pharmacopeia
GET
/api/v1/drug/dextran-70

Mechanism of action

Sourced from openFDA

Mechanism-of-action classes: Osmotic Activity; Structural Macromolecules; Tissue Plasminogen Activator Inhibitors.

Tissue Plasminogen Activator

Indications

Sourced from openFDA
  • Uses relieves redness of the eye due to minor eye irritations as a lubricant to prevent further irritation or to relieve dryness of the eye

Dosage & administration

Sourced from openFDA

Directions Instill 1 or 2 drops in the affected eye(s) up to 4 times daily

Warnings & precautions

Sourced from openFDA

For external use only Ask a doctor before use if you have narrow angle glaucoma When using this product pupils may become enlarged temporarily to avoid contamination, do not touch tip of container to any surface. Replace cap after using if solution changes color or becomes cloudy, do not use overuse may produce increased redness of the eye remove contact lens before using Stop use and ask a doctor if you experience eye pain changes in vision continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
10 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Ocular Hyperaemia330%
  2. 2Blindness220%
  3. 3Chronic Kidney Disease110%
  4. 4Completed Suicide110%
  5. 5Depressed Level Of Consciousness110%
  6. 6Disease Progression110%
  7. 7Drug Toxicity110%
  8. 8Eye Haemorrhage110%
  9. 9Eye Infection110%
  10. 10Eye Irritation110%
  11. 11Eye Pain110%
  12. 12Hypertension110%
  13. 13Infarction110%
  14. 14Instillation Site Pain110%
  15. 15Lung Consolidation110%

Literature

View JSON

Recent PubMed references pinned to Dextran 70 as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 246 ClinicalTrials.gov registrations naming Dextran 70 as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Dextran 70 work?
Mechanism-of-action classes: Osmotic Activity; Structural Macromolecules; Tissue Plasminogen Activator Inhibitors.
What is Dextran 70 used for?
According to FDA labeling, Dextran 70 carries indications including: Uses relieves redness of the eye due to minor eye irritations as a lubricant to prevent further irritation or to relieve dryness of the eye. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Dextran 70?
Dextran 70 is classified as Plasma Volume Expander, Osmotic Activity, Structural Macromolecules, Tissue Plasminogen Activator Inhibitors, Increased Intravascular Volume.
What are the brand names for Dextran 70?
Dextran 70 is marketed under brand names including Bion Tears, Hyskon, Tears Naturale Forte.
Note. Data for dextran-70 is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients